Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma

Seattle Genetics (Nasdaq:SGEN) announced on 2/11/19 that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for Adcetris (brentuximab vedotin) to include ADCETRIS in combination with AVD (Adriamycin®, vinblastine and dacarbazine) in adults patients with previously untreated CD30+ stage IV classical Hodgkin lymphoma (HL).